Table 1.
Cytogenetic and clinical characteristics of patients
| Diagnosis | Cytogenetic data (HCs) | n | Median age, y (range) |
|---|---|---|---|
| RA | 46,XX/46,XY | 5 | 64 (49-80) |
| RCMD | 46,XX/46,XY | 6 | 62 (52-76) |
| −Y | 2 | 61 (56-67) | |
| del(20)(q11q13) | 1 | 70 | |
| inv(7)(q21q31) | 1 | 70 | |
| RCMD-RS | 46,XX/46,XY | 7 | 68 (58-83) |
| −X | 1 | 63 | |
| RAEB I | 46,XX/46,XY | 6 | 63 (53-70) |
| del(11)(q23) | 1 | 63 | |
| Complex aberrations | 1 | 84 | |
| RAEB II | 46,XX/46,XY | 3 | 63 (36-78) |
| Complex aberrations | 3 | 74 (68-84) | |
| −7/7q− alone | 2 | 47 (23-71) | |
| +8 | 2 | 70 (69-71) | |
| +11 | 1 | 80 | |
| 5q Syndrome | del(5)(q13q31) | 1 | 64 |
| AML M0 | 46,XY | 1 | 68 |
| AML M1 | 46,XX/46,XY | 4 | 65 (58-74) |
| Complex aberrations | 3 | 53 (30-66) | |
| 11q23 aberrations | 2 | 57 (52-62) | |
| t(3;8)(q26;q24) | 1 | 49 | |
| AML M2 | 46,XX/46,XY | 6 | 63 (51-69) |
| t(8;21)(q22;q22) | 1 | 46 | |
| AML M3 | t(15;17)(q22;q21) | 2 | 64 (54-75) |
| AML M4 | 46,XX/46,XY | 10 | 55 (27-74) |
| inv(16)(p13;q22) | 1 | 57 | |
| 11q23 aberrations | 3 | 60 (39-71) | |
| −7/7q− alone | 3 | 76 (65-83) | |
| +8 | 1 | 59 | |
| Complex aberrations | 1 | 74 | |
| AML M5 | 46,XX/46,XY | 4 | 57 (51-63) |
| 11q23 aberrations | 1 | 26-55 | |
| +8 | 1 | 33 | |
| del(1)(p35),+21 | 1 | 69 | |
| AML M6 | 46,XY | 1 | 60 |
| Complex aberrations | 1 | 32 | |
| +8 | 1 | 19 | |
| del(9)(q22) | 1 | 71 | |
| del(5)(q13q31) | 1 | 56 |
RCMD indicates refractory cytopenia with multilineage dysplasia; and RCMD-RS, RCMD with ringed sideroblasts.